Clarivate Plc - CLVT STOCK NEWS

Clarivate (NYSE: CLVT) has launched Research Horizon Navigator, an AI-native module within InCites Benchmarking & Analytics, designed to identify emerging research topics and future breakthrough areas. Utilizing data from the Web of Science Core Collection and a novel methodology by the Institute for Scientific Information, the tool highlights new research trends and provides insights for strategic investments. Research Horizon Navigator, available to InCites subscribers, offers interactive visualizations and identifies key contributors. Applications include technology watch, collaboration, funding program management, and research assessment, with continuous enhancements based on community feedback.

Clarivate has partnered with HealthWise Data to integrate Social Determinants of Health (SDoH) attributes into its Real-World Data (RWD) repository. This collaboration aims to enhance patient insights and address healthcare equity by incorporating factors like income, education, and ethnicity. The integration will provide healthcare professionals with comprehensive data to improve patient outcomes and public health interventions.

Bob Morrison, VP of RWD Data Strategy and Operations at Clarivate, emphasizes the milestone's significance in delivering transformative insights. Anne Smith, CEO of HealthWise Data, highlights the improved patient view and outcomes resulting from the partnership. The enhanced RWD is expected to aid in identifying at-risk populations and facilitating targeted early prevention measures.

Clarivate announced the automatic conversion of its 5.25% Series A Mandatory Convertible Preferred Shares into ordinary shares on June 3, 2024. Shareholders will receive 3.8462 ordinary shares per Preferred Share, with cash paid for fractional shares. A final quarterly cash dividend of $1.3125 per Preferred Share will be distributed to holders of record as of May 15, 2024. This move aligns with Clarivate's strategy to simplify its capital structure.

Clarivate announces that 500 institutions, including Florida Atlantic University, have adopted its Rialto™ books marketplace solution. This highlights Rialto's rapid success in enhancing library collection management globally. The platform integrates with Alma, enabling real-time budget tracking and efficient resource ordering. Rialto offers features like AI-driven recommendations, a comprehensive marketplace, and seamless workflows to improve library operations.

Clarivate Plc (NYSE: CLVT), a global provider of transformative intelligence, announced its participation in two investor conferences in June 2024.

CEO Jonathan Gear will present at the William Blair Growth Stock Conference on June 4 at 2:00 p.m. Central Time (3:00 p.m. Eastern Time), accessible via live webcast.

CFO Jonathan Collins will present at the Stifel Cross Sector Insight Conference on June 5 at 3:35 p.m. Eastern Time, also accessible via live webcast.

Replays of both webcasts will be available on Clarivate's investor relations website for 90 days.

On May 22, 2024, Clarivate released its 'Medical Technologies to Watch in 2024' report, spotlighting five breakthrough medical technologies projected to generate significant clinical and commercial impact. These technologies include pulsed field ablation devices for atrial fibrillation, advanced diabetes care devices, neurostimulation devices, surgical robotics, and renal denervation technology for hypertension management. The report forecasts these technologies will generate over $1 billion in market value or achieve double-digit growth within the next five years. Challenges such as shifting service sites, global supply chain issues, and evolving policy landscapes are also acknowledged.

Clarivate has released its Trademark Filing and Litigation Trends 2024 Report, highlighting a return to stability and growth in trademark filing activity globally. The report analyzes trademark registers from the U.S., EU, U.K., Mainland China, Japan, and South Korea, revealing that 2023 exhibited stable trademark filing activities surpassing pre-COVID levels, especially in the U.S., EU, and South Korea. The U.K. demonstrated sustained high growth, while Japan and Mainland China showed slower growth. Key sectors driving trademark applications include retail and business services, technology, and technical services. Mainland China and U.S. applicants led in filing applications across multiple regions, with L'Oreal emerging as a leading filer in several registers.

Clarivate has launched the Trademark Watch Analyzer, an AI-enhanced solution aimed at improving trademark protection. Announced at the 2024 International Trademark Association Annual Meeting, this tool integrates global trademark and case law data, in-house IP expertise, and advanced AI technology. The analyzer covers trademark datasets from 258 countries and 191 trademark registers, along with data from over 7 million trademark litigation cases. This system automates key trademark watching tasks and prioritizes result sets, allowing clients to rank results based on success or opposition chances. According to CompuMark data, trademark applications have doubled since 2014, increasing the need for vigilant trademark monitoring. Gordon Samson, Clarivate's President of Intellectual Property, emphasized that this solution helps clients save time, cost, and resources while ensuring global trademark monitoring and automated alerts.

Clarivate released the 2024 Non-Practicing Entity (NPE) Global Litigation Report, detailing NPE enforcement activities and patent challenges globally. The U.S., Germany, and Mainland China lead in NPE litigation cases, with the U.S. accounting for 97.2% from 2018-2023, Germany 1.8%, and China 0.4%. The report notes a 43% decrease in U.S. NPE cases, a 600% increase in China, and a decline in Germany from 2018. The report found that overall NPE infringement actions declined globally from 2012-2019 and stabilized at around 2,000 cases per year starting in 2020. It also highlights that NPEs face higher patent invalidation rates compared to non-NPEs, indicating potential patent quality issues.